ArticleHepatology (Baltimore, Md.)2019
The Hepatitis C Virus Care Continuum: Linkage to Hepatitis C Virus Care and Treatment Among Patients at an Urban Health Network, Philadelphia, PA.
Article in Hepatology (Baltimore, Md.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07560046 (Combating Related Epidemics in HCV Through Simplified Testing and Treatment. A Cluster Randomized Trial of Point-of-care Hepatitis C Testing and Treatment Among Key Populations), which is not on this map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Combating Related Epidemics in HCV Through Simplified Testing and Treatment. A Cluster Randomized Trial of Point-of-care Hepatitis C Testing and Treatment Among Key Populations
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Barriers and facilitators to hepatitis C screening and treatment for people with lived experience of homelessness: A mixed-methods systematic review.Health expectations : an international journal of public participation in health care and health policy · 2022Pooled it
- Infectious Diseases Among People Experiencing Homelessness: A Systematic Review of the Literature in the United States and Canada, 2003-2022.Public health reports (Washington, D.C. : 1974)Pooled it
- Mobile Telemedicine for Treating Chronic Hepatitis C Among Rural People Who Inject Drugs: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Trial
- Health Benefits, Costs, and Cost-Effectiveness of Jail-Based Hepatitis C Elimination Strategies.JAMA internal medicine · 2026Article
- Potential Cost-Effectiveness of Machine Learning-Enabled Primary Care Identification of Hepatitis C Virus Patients in the US.Viruses · 2026Article
- Progressing towards global hepatitis C elimination: a systematic review and meta-analysis of care cascades in key populations.The Lancet regional health. Western Pacific · 2026Article
- Direct-acting antivirals for chronic hepatitis C infection: a protocol for a systematic review of observational studies.Systematic reviews · 2026Article
- Observational
- From Education to Action-The Impact of Hepatitis C Micro-Elimination Education on Healthcare Provider Confidence and Linkage to Care: A Quasi-Experimental Study.Health science reports · 2025Article
- Road to Hepatitis C Elimination in Israel: Improvements in Linkage to Care (2009-2020).Advances in therapy · 2025Article
- Clinical- and Cost-Effectiveness of Liver Disease Staging in Hepatitis C Virus Infection: A Microsimulation Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- People With HIV Are More Likely to Clear Hepatitis C: Role of Ryan White Services, Philadelphia, Pennsylvania, United States.Open forum infectious diseases · 2025Article
- Test characteristics for combining non-invasive liver fibrosis staging modalities in individuals with Hepatitis C virus.Journal of viral hepatitis · 2024Article
- Article
- Article
- Hepatitis C Cascades: Data to Inform Hepatitis C Elimination in the United States.Public health reports (Washington, D.C. : 1974) · 2023Review
- Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts.Journal of general internal medicine · 2022Review
- Projected Long-Term Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hepatitis C Outcomes in the United States: A Modeling Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Closing the hepatitis C treatment gap: United States strategies to improve retention in care.Journal of viral hepatitis · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
Improving care and treatment for persons infected with hepatitis C virus (HCV) can reduce HCV-related morbidity and mortality. Our primary objective was to examine the HCV care continuum among patients receiving care at five federally qualified health centers (FQHCs) in Philadelphia, PA, where a testing and linkage to care program had been established. Among the five FQHCs, one served a homeless population, two served public housing residents, one served a majority Hispanic population, and the last, a "test and treat" site, also provided HCV treatment to patients. We analyzed data from electronic health records of patients tested for HCV antibody from 2012 to 2016 and calculated the percentage of patients across nine steps of the HCV care continuum ranging from diagnosis to cure. We further explored factors associated with successful patient navigation through two steps of the continuum using multivariable logistic regression. Of 885 chronically infected patients, 92.2% received their RNA-positive result, 82.7% were referred to an HCV provider, 69.4% were medically evaluated by the provider, 55.3% underwent liver disease staging, 15.0% initiated treatment, 12.0% completed treatment, 8.7% were assessed for sustained virologic response (SVR), and 8.0% achieved SVR. Regression results revealed that test and treat site patients were significantly more likely to be medically evaluated (adjusted odds ratio [aOR], 2.76; 95% confidence interval [CI], 1.82-4.17) and to undergo liver disease staging (aOR, 1.92; 95% CI, 1.02-2.86) than patients at the other FQHCs combined. Conclusion: In this US urban setting, over two thirds of HCV-infected patients were linked to care; although treatment uptake was low overall, it was highest at the test and treat site; scaling up treatment services in HCV testing settings will be vital to improve the HCV care continuum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.